Pfizer, Ergonex enter PAH drug deal

Twitter icon
Facebook icon
LinkedIn icon
e-mail icon
Google icon

Pfizer and Ergonex Pharma of Appenzell, Switzerland, have entered into an agreement for terguride, an oral, potent antagonist of 5-HT2B and serotonin receptors used in the treatment for pulmonary arterial hypertension (PAH).

Under the terms of the agreement, Pfizer will gain rights to market terguride and also be involved in the completion of the ongoing Phase 2 trial for the drug. According to New York City-based Pfizer, Ergonex will receive royalties and milestone payments for drug sales.

According to Pfizer, terguride has received orphan drug designation in the U.S. and the EU for PAH and is currently approved in Japan for hyperprolactinemia.